Welcome to our dedicated page for Polyrizon news (Ticker: PLRZ), a resource for investors and traders seeking the latest updates and insights on Polyrizon stock.
Polyrizon Ltd. (Nasdaq: PLRZ) generates news as a development-stage biotechnology company focused on intranasal hydrogels and barrier-forming nasal sprays. Company announcements highlight progress across its Capture and Contain™ (C&C) and Trap & Target™ (T&T) platforms, including updates on allergy, viral exposure reduction, and intranasal drug delivery programs.
Readers following Polyrizon news can expect coverage of preclinical study results, regulatory interactions, and product branding milestones. Recent press releases describe positive in-vitro data for PL-14 Allergy Blocker, including allergen-blocking performance compared with a standard comparator, and the completion of a branding process that will see PL-14 marketed as NASARIX™. Other updates focus on PL-16 Viral Blocker, a non-pharmacological intranasal hydrogel spray designed to form a temporary physical barrier on the nasal mucosa, with reported preclinical evidence of protection against certain respiratory viruses.
Polyrizon also reports on the advancement of its intranasal naloxone hydrogel within the Trap & Target™ platform. News items detail mucoadhesion and permeation studies comparing the formulation to a marketed intranasal naloxone product, as well as broader commentary on the potential role of enhanced mucosal residence time in emergency opioid overdose reversal.
In addition to R&D and regulatory milestones, Polyrizon’s news flow includes strategic and corporate developments. The company has disclosed plans to explore revenue-generating investment opportunities in sectors such as defense, aviation, artificial intelligence, and real assets, alongside continued focus on its core medical pipeline. Investors and observers can use this news stream to monitor scientific progress, FDA-related steps such as pre-submission meetings and Pre-Request for Designation filings, capital structure actions like reverse share splits, and broader strategic decisions that may influence the PLRZ stock story over time.
Polyrizon (PLRZ) closed its previously announced registered direct offering and concurrent private placement raising approximately $4.0 million in aggregate gross proceeds from a single institutional investor.
The company sold 333,333 Units/Pre-Funded Units, each comprising one Ordinary Share (or one Pre-Funded Warrant for one Ordinary Share) and one Common Warrant, at a combined offering price of $12.00 per Unit (or $11.99999 per Pre-Funded Unit). In the registered direct deal, Polyrizon issued 232,500 Ordinary Shares and 30,000 Pre-Funded Warrants, and in the private placement it issued 70,833 PIPE Pre-Funded Warrants and 333,333 PIPE Common Warrants with an exercise price of $12.00 per share. The transactions closed on September 4, 2026, and the company expects to use the net proceeds for general corporate purposes and working capital.
Polyrizon (PLRZ) entered definitive agreements on September 3, 2026 for a registered direct offering and concurrent private placement totaling approximately $4.0 million with a single institutional investor.
The financing involves 333,333 Units (or Pre-Funded Units), each with one Ordinary Share (or one Pre-Funded Warrant) and one Common Warrant, at $12.00 per Unit ($11.99999 per Pre-Funded Unit). The registered direct portion covers 232,500 Ordinary Shares and 30,000 Pre-Funded Warrants, while the private placement adds 70,833 PIPE Pre-Funded Warrants and 333,333 PIPE Common Warrants, all with a $12.00 exercise price for the Common Warrants. Closing is expected on or about September 4, 2026, subject to customary conditions. Net proceeds, together with existing cash, are expected to fund general corporate purposes and working capital. After completion, assuming full exercise of all Pre-Funded Warrants, Polyrizon will have 2,806,233 Ordinary Shares outstanding.
Polyrizon (PLRZ) has completed contracting with all five U.S. clinical sites for its first-in-human study of NASARIX™ Allergy Blocker (PL-14), advancing the program into study execution.
The prospective, multicenter, randomized, single-blind, two-arm trial in seasonal allergic rhinitis will enroll up to 120 patients, randomized 1:1 to receive NASARIX or an isotonic saline nasal spray control. The primary efficacy endpoint is the difference between treatment groups in mean daily reflective Total Nasal Symptom Score (rTNSS) over the first 14 treatment days, with safety assessed via treatment-emergent adverse events and local/overall tolerability. Secondary measures are expected to include instantaneous TNSS (iTNSS), quality of life, symptom-free days, and use of permitted relief medication. Enrollment is planned to align with relevant allergy seasons, using local pollen counts and weather conditions to guide recruitment timing.
Polyrizon (Nasdaq: PLRZ) announced completion of contracting with all five U.S. clinical sites selected for its first-in-human study of NASARIX™ Allergy Blocker (PL-14), an intranasal hydrogel-based product for seasonal allergic rhinitis. This operational milestone enables progression from clinical preparation toward execution.
The prospective, multicenter, randomized, single-blind, two-arm trial is designed to enroll up to 120 patients, randomized 1:1 to NASARIX or isotonic saline nasal spray. The primary endpoint is mean daily reflective Total Nasal Symptom Score over the first 14 treatment days, with additional safety, tolerability and quality-of-life assessments. Polyrizon is initiating patient pre-screening and preparing enrollment to coincide with relevant allergy seasons.
Polyrizon (Nasdaq: PLRZ) reported successful completion of the biocompatibility evaluation program for its NASARIX™ Allergy Blocker nasal spray, with all required biological safety tests meeting predefined acceptance criteria.
The ISO 10993- and FDA-guided program strengthens the non-clinical safety package and supports advancement toward a first-in-human clinical trial and potential commercialization.
Polyrizon (Nasdaq: PLRZ) received central IRB approval from BRANY on June 18, 2026 to begin its first human clinical trial of NASARIX™, a nasal spray allergy blocker. The approved study will compare NASARIX to saline in patients with seasonal allergic rhinitis, assessing efficacy, safety, tolerability, and quality-of-life outcomes. The master protocol approval is valid through June 17, 2027, while each clinical site must still secure its own site-specific IRB approval before activating sites and enrolling participants.
Polyrizon (Nasdaq: PLRZ) announced publication of U.S. patent application US 2024/0358741 A1 for its Trap & Target™ mucoadhesive polymer platform for nasal drug delivery.
The biocompatible hydrogels aim to enhance mucosal retention, drug absorption, and sprayable film-forming delivery across nasal and other mucosal routes.
Polyrizon (Nasdaq: PLRZ) signed agreements with a leading European university medical center and a specialized CRO to run a human performance and characterization study of its NASARIX™ (PL-14) Allergy Blocker.
The single-site study in healthy participants will measure nasal residence time, informing barrier duration and supporting the company’s V&V program and planned FDA submissions, under MDR and GCP standards.
Polyrizon (Nasdaq: PLRZ) announced that the European Patent Office has completed technical preparations to publish its European patent application EP 4751737, titled “Mucoadhesive Polymers for Nasal Drug Delivery.”
The application covers Polyrizon’s Trap & Target™ mucoadhesive nasal polymer platform, aimed at improving nasal formulation retention, drug absorption and delivery efficiency, and strengthening the company’s intellectual property position in European markets, subject to successful examination and potential grant.
Polyrizon (Nasdaq: PLRZ) signed agreements with two additional U.S. clinical sites, bringing the total to three major centers contracted for its upcoming NASARIX™ (PL-14) multi-center trial in seasonal allergic rhinitis.
The study will test safety, tolerability, and efficacy of NASARIX™ Allergy Blocker, an intranasal hydrogel designed to form a protective barrier against airborne allergens, at up to five U.S. sites under GCP standards.